Serological response to HPV16 in CIN-III and cervical-cancer patients. Case-control studies in Spain and Colombia

International Journal of Cancer

Volumn 66, Issue 1, 1996, Pages 70-74

  De Sanjosé, Silvia ^a,m   Hamsîíková, Eva ^b   Muñoz, Nubia ^c   Bosch, F Xavier ^a   Hofmannová, Vanda ^b   Gili, Miguel ^d   Izarzugaza, Isabel ^e   Viladiu, Pau ^a,f   Tormo, Maria José ^g   Moreo, Pilar ^h   Muñoz, Maria Teresa ⁱ   Ascunce, Nieves ^j   Tafur, Luis ^k   Shah, Keerti V ^l   Vonka, Vladimir ^b  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b INSTITUTE OF HEMATOLOGY AND BLOOD TRANSFUSION   (Czech Republic)

^c INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^d HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^e Registro del Cancer de Euzkadi   (Spain)

^f Unitat d'Epidemiolgia I Registre C   (Spain)

^g Consejeria Sanid Y Asuntos Sociales ^*  (Spain)

^h Inst Munic de Salud Pub Zaragoza   (Spain)

ⁱ Delegacion Terr de Bienestar Social   (Spain)

^j Departamento de Salud   (Spain)

^k UNIVERSIDAD DEL VALLE   (Colombia)

^l JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^m HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; VIRUS DNA;

CONFERENCE PAPER; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PAPILLOMA VIRUS; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA;

ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CARCINOMA; CARCINOMA IN SITU; CASE-CONTROL STUDIES; CERVICAL INTRAEPITHELIAL NEOPLASIA; COLOMBIA; FEMALE; HUMANS; PAPILLOMAVIRIDAE; SPAIN; UTERINE CERVICAL NEOPLASMS;

EID: 9244244182     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19960328)66:1<70::AID-IJC13>3.0.CO;2-F     Document Type: Conference Paper

References (13)

1. CHRISTENSEN, N.D., HOPPFL, R., Di ANGELO, S.L., CLADEL, N.M., PATRICK, S.D., WELSH, P.A., BUDGEOIN, L.R., REED, C.A. and KREIDER, W., Assembled baculovirus-expressed human-papillomavirus-type-11 L1 capsid protein virus-like particles are recognized by monoclonal antibodies and induced titers of neutralizing antibodies. J. gen Virol., 75, 2271-2276 (1994a).
2. CHRISTENSEN, N.D., KIRNBAUER, R., SCHILLER. J.T., GHIM, S.J., SCHLEGEL, R., JENSON, A.B. and KREIDER, J.V., Human papiilomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes. Virology, 206, 329-336 (1994b).
3. DILLNER, J., Antibody response to defined HPV epitopes in cervical neoplasia. Papillomavirus Rep., 5, 35-41 (1994).
4. DILLNER, J., DILLNER, L., UTTER, G., EKLUND, C., ROTOLA, A., COSTA, S. and DILUCA, D., Mapping of linear epitopes of human papillomavirus type 16: the L1 and L2 open reading frames. Int. J. Cancer, 45, 529-535 (1990).
5. GUERRERO, E. and 13 OTHERS, A comparison of Virapap, Southern hybridization and polymerase-chain-reaction methods for human papillomavirus identification in an epidemiological investigation of cervical cancer. J. clin Microbiol., 30, 2951-2959 (1992).
6. HAMSÎÍKOVÁ, E., NOVÁK, J., HOFMANNOVÁ, V., MUÑOZ, N., BOSCH, F.X., DE SANJOSÉ, S., SHAH, K.V., ROTH, Z. and VONKA, V., Presence of antibodies to seven human-papillomavirus-type-16-derived peptides in cervical-cancer patients and healthy controls. J. infec. Dis., 170, 1424-1431 (1994).
7. KRCHNÁK, V., VÁGNER, J., SUCHÁNKOVÁ, A., KRCMÁR, M., RITTEROVÁ, L. and VONKA, V., Synthetic peptides derived from E7 region of human papillomavirus type 16 used as antigens in ELISA. J. gen. Virol., 71, 2719-2724 (1990).
8. KIRNBAUER, R., HUBBERT, N.L., WHEELER, C.M., LOWY, D.R. and SCHILLER, J.T., A virus-like-particle-enzyme-linked immunoabsorbent assay detects serum antibodies in a majority of women infected with human papillomavirus type 16. J. nat. Cancer Inst., 86, 44-49 (1994).
9. MORENO, V. and 12 OTHERS, Risk factors for progression of cervical intraepithelial neoplasm grade III to invasive cervical cancer. Cancer Epidemiol. Biomarkers Prev., 4, 459-467 (1995).
10. MUÑOZ, N. and 17 OTHERS, The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain. Int. J. Cancer, 52, 743-749 (1992).
11. NONNENMACHER, B., HUBBERT, N.L., KINBAUER, R., SHAH, K.V , MUÑOZ, N., BOSCH, F.X., DE SANJOSÉ, S., VISCIDI, R., LOWY, D.R. and SCHILLER, J.T. and SEROLOGICAL RESPONSE TO HUMAN-PAPILLOMAVIRUS-TYPE-16 VIRUS-LIKE PARTICLES IN HPV-16-DNA-POSITIVE INVASIVE CERVICAL CANCER AND CERVICAL INTREPITHELlAL NEOPLASIA GRADE III. PATIENTS AND CONTROLS FROM COLOMBIA AND SPAIN. J. INFECT. Dis., 172, 19-24 (1995).
12. SUN, Y., ELU-NETO, J., BOSCH, F.X., MUÑOZ, N., BOOTH, M., WALBOOMERS, J.M.M., SHAH, K.V. and VISCIDI, R.P., Human-papillomavirus-related serological markers of invasive cervical carcinoma in Brazil. Cancer Epidemiol. Biomarkers Prev., 3, 341-347 (1994).
13. VISCIDI, R.P., SUN, Y., TZUARKI, B., BOSCH, F.X., MUÑOZ, N and SHAH, K.V., Serologic response in human-papillomavirus-associated invasive cervical cancer, Int. J. Cancer, 55, 780-784 (1993).